Alcresta Therapeutics

Alcresta Therapeutics

医疗设备制造业

Newton,MA 2,600 位关注者

Fulfilling potential: With the Science of Enzymes

关于我们

Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.

网站
http://www.alcresta.com
所属行业
医疗设备制造业
规模
11-50 人
总部
Newton,MA
类型
私人持股
创立
2011

地点

  • 主要

    One Newton Executive Park

    Suite 100

    US,MA,Newton,02462

    获取路线

Alcresta Therapeutics员工

动态

相似主页

查看职位

融资

Alcresta Therapeutics 共 5 轮

上一轮

未知

US$10,000,004.00

Crunchbase 上查看更多信息